UniProt Q6DRA1
Beta-lactamase (Q6DRA1)
Beta-lactamase (UniProt Q6DRA1), EC 3.5.2.6: 35 experimental structures on GenesisL1, 18 ligands bound, 170 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q6DRA1
- Protein
- Beta-lactamase
- EC
- 3.5.2.6
- Experimental structures
- 35
- Predicted models
- 0
- Ligands
- 18
- Pockets
- 170 · 14 records with a druggable one
Structures
35 records of Q6DRA1 in the MolNFT archive: 35 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 4U0T | Crystal structure of ADC-7 beta-lactamase | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 4U0T | Crystal structure of adc-7 beta-lactamase | x-ray diffraction | A, B, C, D, E, F, G, H | — | — |
| 4U0X | Structure of ADC-7 beta-lactamase in complex with boronic acid inhibitor S02030 | x-ray diffraction | B, A, C, D | — | — |
| 4U0X | Structure of adc-7 beta-lactamase in complex with boronic acid inhibitor S02030 | x-ray diffraction | B, A, C, D | — | — |
| 5W12 | ADC-7 in complex with boronic acid transition state inhibitor EC04 | x-ray diffraction | A, B, C, D | 9TG | 10 (best 0.74) |
| 5W12 | Adc-7 in complex with boronic acid transition state inhibitor EC04 | x-ray diffraction | A, B, C, D | 9TG | — |
| 5W13 | ADC-7 in complex with boronic acid transition state inhibitor SM23 | x-ray diffraction | A, B, C, D | SM2 | 14 (best 0.69) |
| 5W13 | Adc-7 in complex with boronic acid transition state inhibitor SM23 | x-ray diffraction | A, B, C, D | SM2 | — |
| 5W14 | ADC-7 in complex with boronic acid transition state inhibitor S03043 | x-ray diffraction | A, B, C, D | 9TJ | 10 (best 0.74) |
| 5W14 | Adc-7 in complex with boronic acid transition state inhibitor S03043 | x-ray diffraction | A, B, C, D | 9TJ | — |
| 5WAC | ADC-7 in complex with boronic acid transition state inhibitor CR157 | x-ray diffraction | A, B, C, D | A1M | 14 (best 0.66) |
| 5WAC | Adc-7 in complex with boronic acid transition state inhibitor CR157 | x-ray diffraction | A, B, C, D | A1M | — |
| 5WAD | ADC-7 in complex with boronic acid transition state inhibitor CR161 | x-ray diffraction | A, B, C, D | QQZ, PO4 | 13 (best 0.71) |
| 5WAD | Adc-7 in complex with boronic acid transition state inhibitor CR161 | x-ray diffraction | A, B, C, D | QQZ, PO4 | — |
| 5WAE | ADC-7 in complex with boronic acid transition state inhibitor CR167 | x-ray diffraction | A, B, C, D | A1J | 11 (best 0.74) |
| 5WAE | Adc-7 in complex with boronic acid transition state inhibitor CR167 | x-ray diffraction | A, B, C, D | A1J | — |
| 5WAF | ADC-7 in complex with boronic acid transition state inhibitor CR192 | x-ray diffraction | A, B, C, D | A0Y | — |
| 5WAF | Adc-7 in complex with boronic acid transition state inhibitor CR192 | x-ray diffraction | A, B, C, D | A0Y | — |
| 5WAG | ADC-7 in complex with boronic acid transition state inhibitor S06017 | x-ray diffraction | B, A, C, D | A0V | 11 (best 0.71) |
| 5WAG | Adc-7 in complex with boronic acid transition state inhibitor S06017 | x-ray diffraction | B, A, C, D | A0V | — |
| 6PWL | ADC-7 in complex with boronic acid transition state inhibitor LP06 | x-ray diffraction | A, B, C, D | LP0, GLY | 10 (best 0.74) |
| 6PWL | Adc-7 in complex with boronic acid transition state inhibitor LP06 | x-ray diffraction | A, B, C, D | LP0 | — |
| 6PWM | ADC-7 in complex with Beta-lactam antibiotic ceftazidime | x-ray diffraction | A, B, C, D | CAZ, GLY | 12 (best 0.74) |
| 6PWM | Adc-7 in complex with beta-lactam antibiotic ceftazidime | x-ray diffraction | A, B, C, D | CAZ | — |
| 6TZF | ADC-7 in complex with boronic acid transition state inhibitor S17079 | x-ray diffraction | A, B, C, D | KAS | 15 (best 0.62) |
| 6TZF | Adc-7 in complex with boronic acid transition state inhibitor S17079 | x-ray diffraction | A, B, C, D | KAS | — |
| 6TZG | ADC-7 in complex with boronic acid transition state inhibitor S17083 | x-ray diffraction | A, B, C, D | PKY | 15 (best 0.62) |
| 6TZG | Adc-7 in complex with boronic acid transition state inhibitor S17083 | x-ray diffraction | A, B, C, D | PKY | — |
| 6TZH | ADC-7 in complex with boronic acid transition state inhibitor S06015 | x-ray diffraction | A, B, C, D | ERF, GLY, PO4 | 12 (best 0.70) |
| 6TZH | Adc-7 in complex with boronic acid transition state inhibitor S06015 | x-ray diffraction | A, B, C, D | ERF, PO4 | — |
| 6TZI | ADC-7 in complex with boronic acid transition state inhibitor PFC_001 | x-ray diffraction | A, B, C, D | P1K | 13 (best 0.63) |
| 6TZI | Adc-7 in complex with boronic acid transition state inhibitor PFC_001 | x-ray diffraction | A, B, C, D | P1K | — |
| 6TZJ | ADC-7 in complex with boronic acid transition state inhibitor ME_096 | x-ray diffraction | A, B, C, D | PKV, GLY | 10 (best 0.72) |
| 6TZJ | Adc-7 in complex with boronic acid transition state inhibitor ME_096 | x-ray diffraction | A, B, C, D | PKV | — |
| 8FQM | ADC-7 in complex with boronic acid transition state inhibitor MB076 | x-ray diffraction | A, B, C, D | YDB | — |
Ligands
- GLY · Glycine · in 4 records
- PO4 · Phosphate ion · in 4 records
- 9TG · 3-[(2R)-2-borono-2-{[(thiophen-2-yl) acetyl]amino}ethyl]benzoic acid · in 2 records
- 9TJ · 3-{1-[(2R)-2-borono-2-{[(thiophen-2-yl) acetyl]amino}ethyl]-1H-1,2,3-triazol-4-yl}benzoic acid · in 2 records
- A0V · 1-{[hydroxy(phosphonooxy)boranyl]methyl}-1H-1,2,3-triazole-4-carboxylic acid · in 2 records
- A0Y · phosphonooxy-[[[4-(1~{H}-1,2,3,4-tetrazol-5-yl)-2-(trifluoromethyl)phenyl]sulfonylamino]methyl]borinic acid · in 2 records
- A1J · 3-(5,7,7-trihydroxy-2,2,7-trioxo-6-oxa-2lambda~6~-thia-3-aza-7lambda~5~-phospha-5-boraheptan-1-yl)benzoic acid · in 2 records
- A1M · Phosphonooxy-[[[4-(1~{H}-1,2,3,4-tetrazol-5-yl) phenyl]sulfonylamino]methyl]borinic acid · in 2 records
- CAZ · Acylated ceftazidime · in 2 records
- ERF · Phosphonooxy-[(4-thiophen-3-yl-1,2,3-triazol-1-yl) methyl]borinic acid · in 2 records
- KAS · 3-(1-{[hydroxy(phosphonooxy)boranyl]methyl}-1H-1,2,3-triazol-4-yl)benzoic acid · in 2 records
- LP0 · (7Z)-7-(2-amino-1,3-thiazol-4-yl)-1,1,3-trihydroxy-10, 10-dimethyl-1,6-dioxo-2,9-dioxa-5,8-diaza-1lambda~5~-phospha-3-boraundec-7-en-11-oic acid · in 2 records
- P1K · Phosphonooxy-[[4-[[2,2,2-tris(fluoranyl) ethylsulfonylamino]methyl]-1,2,3-triazol-1-yl]methyl]borinic acid · in 2 records
- PKV · [4-[[(4-methylphenyl)sulfonylamino]methyl]-1,2,3-triazol-1-yl]methyl-phosphonooxy-borinic acid · in 2 records
- PKY · [4-(3-aminocarbonylphenyl)-1,2,3-triazol-1-yl]methyl-phosphonooxy-borinic acid · in 2 records
- QQZ · phosphonooxy-[[[6-(1~{H}-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]sulfonylamino]methyl]borinic acid · in 2 records
- SM2 · (1R)-1-(2-thienylacetylamino)-1-(3-carboxyphenyl) methylboronic acid · in 2 records
- YDB · 1-[(2R)-2-{2-[(5-amino-1,3,4-thiadiazol-2-yl)sulfanyl]acetamido}-2-boronoethyl]-1H-1,2,3-triazole-4-carboxylic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.